Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches
| dc.contributor.author | Reid, A.T. | |
| dc.contributor.author | Veerati, P.C. | |
| dc.contributor.author | Gosens, R. | |
| dc.contributor.author | Bartlett, N.W. | |
| dc.contributor.author | Wark, P.A. | |
| dc.contributor.author | Grainge, C.L. | |
| dc.contributor.author | Stick, S.M. | |
| dc.contributor.author | Kicic, Anthony | |
| dc.contributor.author | Moheimani, F. | |
| dc.contributor.author | Hansbro, P.M. | |
| dc.contributor.author | Knight, D.A. | |
| dc.date.accessioned | 2019-11-09T21:58:59Z | |
| dc.date.available | 2019-11-09T21:58:59Z | |
| dc.date.issued | 2018 | |
| dc.identifier.citation | Reid, A.T. and Veerati, P.C. and Gosens, R. and Bartlett, N.W. and Wark, P.A. and Grainge, C.L. and Stick, S.M. et al. 2018. Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches. Pharmacology and Therapeutics. 185: pp. 155-169. | |
| dc.identifier.uri | http://hdl.handle.net/20.500.11937/76808 | |
| dc.identifier.doi | 10.1016/j.pharmthera.2017.12.009 | |
| dc.description.abstract |
© 2017 Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus itself, or have aimed to limit the production of mucus-stimulating cytokines. Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation and highlights both pre-existing and novel therapeutic strategies to combat this pathology. | |
| dc.language | English | |
| dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | |
| dc.subject | Science & Technology | |
| dc.subject | Life Sciences & Biomedicine | |
| dc.subject | Pharmacology & Pharmacy | |
| dc.subject | Goblet cell | |
| dc.subject | Asthma | |
| dc.subject | COPD | |
| dc.subject | Cystic fibrosis | |
| dc.subject | Mucus | |
| dc.subject | Epithelium | |
| dc.subject | Signaling pathways | |
| dc.subject | Therapeutic | |
| dc.subject | micro-RNA | |
| dc.subject | Mechanical stress | |
| dc.subject | Monoclonal antibody therapy | |
| dc.subject | GROWTH-FACTOR RECEPTOR | |
| dc.subject | BRONCHIAL EPITHELIAL-CELLS | |
| dc.subject | RECOMBINANT HUMAN INTERLEUKIN-5 | |
| dc.subject | OBSTRUCTIVE PULMONARY-DISEASE | |
| dc.subject | RESPIRATORY SYNCYTIAL VIRUS | |
| dc.subject | COLONY-STIMULATING FACTOR | |
| dc.subject | CYSTIC-FIBROSIS | |
| dc.subject | MUCUS OVERPRODUCTION | |
| dc.subject | NEBULIZED AMILORIDE | |
| dc.subject | MUCIN PRODUCTION | |
| dc.title | Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches | |
| dc.type | Journal Article | |
| dcterms.source.volume | 185 | |
| dcterms.source.startPage | 155 | |
| dcterms.source.endPage | 169 | |
| dcterms.source.issn | 0163-7258 | |
| dcterms.source.title | Pharmacology and Therapeutics | |
| dc.date.updated | 2019-11-09T21:58:58Z | |
| curtin.department | School of Public Health | |
| curtin.accessStatus | Fulltext not available | |
| curtin.faculty | Faculty of Health Sciences | |
| curtin.contributor.orcid | Kicic, Anthony [0000-0002-0008-9733] | |
| dcterms.source.eissn | 1879-016X | |
| curtin.contributor.scopusauthorid | Kicic, Anthony [6507472922] |